贵州益佰制药股份有限公司2025年年度业绩预告

Core Viewpoint - Guizhou Yibai Pharmaceutical Co., Ltd. is forecasting a significant net loss for the year 2025, with expected losses ranging from 342 million to 285 million yuan [2][3]. Financial Performance Summary - The company anticipates a net profit attributable to shareholders of the parent company for 2025 to be between -342 million yuan and -285 million yuan, indicating a loss [2][3]. - The expected net profit after deducting non-recurring gains and losses is projected to be between -336 million yuan and -280 million yuan [2][3]. - For the previous year, 2024, the total profit was -332.52 million yuan, with a net profit attributable to shareholders of -317.22 million yuan [5]. Earnings Per Share - The earnings per share for the previous year (2024) was reported at -0.402 yuan [6]. Reasons for Expected Loss - The primary reasons for the anticipated loss include a 14% decrease in sales of major products, leading to a decline in revenue, despite an 18% expected reduction in costs [7]. - The company plans to recognize goodwill impairment provisions between 110 million and 132 million yuan, which will further increase the losses [7].